TTI's Important Core Patent Allowed in Europe Important Core Patent Allowed In Europe - Thiogenesis Therapeutics (TTI.v) Announced European Approval
Last week, Thiogenesis Therapeutics (TTI.v) announced the approval of its European patent for "Methods For The Treatment of Cysteamine Sensitive Disorders.".
This patent, set to expire in September 2037, complements previous patent approvals in the United States and Japan with the IP protection aligning with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.
TTI-0102 and Clinical Development
TTI-0102, TTI's lead compound, metabolizes into cysteamine, a precursor to glutathione and one of the body's primary antioxidants, and targets oxidative stress in the mitochondria, a factor in chronic diseases like MELAS, Leigh syndrome, and pediatric MASH.
Notably, TTI-0102’s unique sustained release allows for longer efficacy with fewer side effects and qualifies for the accelerated 505(b)(2) regulatory pathway in the U.S.
Further, TTI plans to initiate Phase 2 trials soon, aiming to provide significant clinical benefits for diseases with high oxidative stress.
Full News Release: https://www.newsfilecorp.com/release/228659
Posted on Behalf of Thiogenesis Therapeutics Corp.